Pfizer Inc. (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Medivation, a biopharmaceutical company focused on developing and commercializing small molecules for oncology, for $81.50 a share in cash for a total enterprise value of approximately $14 billion. The Boards of Directors of both companies have unanimously approved the merger, which is expected to be immediately accretive to Pfizer’s Adjusted Diluted EPS upon closing, approximately $0.05 accretive in the first full year after close with additional accretion and growth anticipated thereafter. Pfizer does not expect the transaction to impact its current 2016 financial guidance.
Morrow Sodali is acting as information agent for this transaction
Related News
Sodali & Co implements US$13bn Sovereign External Debt Restructuring for Republic of Ghana
17 October 2024
Sodali & Co Debt Team supports Ukraine to achieve budget liquidity and financial stability
12 September 2024
Banco Sabadell to file a complaint with the Spanish National Securities Market Commission (CNMV) alleging that BBVA violated takeover regulations
10 May 2024
Morrow Sodali Names Barri Rafferty as CEO of the Americas
05 September 2023
Media enquiries
To contact our global experts for comments please get in touch below.
Contact us chevron_right